



**Islam Quazi Shafique & Co.**  
Chartered Accountants

*Private & Confidential*

**Auditor's Report**  
of  
**Silco Pharmaceuticals Limited**

For the year ended on June 30, 2024

Member firm of



**PRINCIPAL OFFICE**

Gulfesha Plaza (10th Floor)  
Unit # B & C  
8 Shahid Sangbadik Selina Parvin Road  
Boro Moghbazar, Dhaka-1217  
+880-2-48312349  
qsi.esk@gmail.com  
rahman@qsibd.com

**UTTARA BRANCH**

📍 26, ABC Skyrise Tower (6th Floor)  
6B Unit, Shahjalal Avenue Road,  
Sector-04, Uttara, Dhaka-1230  
☎ +8801717 322693  
✉ biplop@qsibd.com  
🌐 www.qsibd.com

**PALTAN BRANCH UNIT-1**

📍 Paramount Heights (Level-5)  
65/2/1, Box Culvert Road,  
Purana Paltan, Dhaka-1000.  
☎ +88 02 223384883  
✉ tariqul@qsibd.com  
islamqshafique@gmail.com

**PALTAN BRANCH UNIT-2**

📍 Paramount Heights (Level-9)  
65/2/1, Box Culvert Road,  
Purana Paltan, Dhaka-1000.  
☎ +8801819 252604  
✉ nasser@qsibd.com  
nasirhfc1986@gmail.com

## **TABLE OF CONTENTS**

<b>Serial No.</b>	<b>Particulars</b>	<b>Page No.</b>
01	Auditors' Report	01-05
02	Statement of Financial Position	06
03	Statement of Profit or Loss and Other Comprehensive Income	07
04	Statement of Changes in Equity	08
05	Statement of Cash Flows	09
06	Notes to the Financial Statements	10-37
07	Schedule of Property, Plant & Equipment (Annexure-A)	38-39
08	Schedule of Right of Use Asset (ROU) (Annexure-B)	40-41



# Islam Quazi Shafique & Co. Chartered Accountants

## INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SILCO PHARMACEUTICALS LIMITED

### Report on the Audit of the Financial Statements

#### Opinion

We have audited the financial statements of Silco Pharmaceuticals Limited (the company) which comprise the Statement of Financial Position as at 30 June 2024 and Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended 30 June 2024, and notes to the financial statements, including a summary of significant accounting policies and other explanatory notes.

In our opinion, the accompanying financial statements of the Company give a true and fair view of the financial position of the Company as at 30 June 2024, and of its financial performance and its cash flows for the year then ended 30 June 2024, in accordance with International Financial Reporting Standards (IFRSs), the company Act 1994 and other applicable laws and regulations.

#### Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Independence and Other Ethical Responsibilities

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), Bangladesh Securities and Exchange Commission (BSEC) and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code and the Financial Reporting Council (FRC) by Laws.

#### Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

S.L.	Key Audit Report	How our audit addressed the key audit matter
1.	<p><b>Appropriateness of revenue recognition and disclosures on the impact of the initial application of IFRS 15.</b></p> <p>Refer to note 22.00 to the financial statements.</p> <p>As described in accounting policy note 2.19 to the financial statements, the Company recognizes revenue upon transfer of control as per the newly adopted IFRS 15:</p>	<p>We assessed the company's process to identify the impact of the revenue accounting standard. Our audit approach consisted testing of the design and operating effectiveness of the internal controls and substantive testing as follows:</p> <ul style="list-style-type: none"> <li>Assessed the environment of the measurement as well as other relevant systems supporting the accounting or revenue.</li> </ul>

Member firm of



#### MUNICIPAL OFFICE

11 Sha Plaza (10th Floor)  
# B & C  
Shahid Sangbadik Selina Parvin Road  
Moghbar, Dhaka-1217  
T: +8802-48312349  
E: sk@gmail.com  
an@qsibd.com

#### UTTARA OFFICE

26, ABC Skyrise Tower (6th Floor)  
6B Unit, Shahjalal Avenue Road.  
Sector-04, Uttara, Dhaka-1230  
T: +8801717322693  
E: biplob@qsibd.com  
www.qsibd.com

#### PALTAN BRANCH UNIT-1

Paramount Heights (Level-5)  
65/2/1, Box Culvert Road,  
Purana Paltan, Dhaka-1000.  
T: +88-02-223384883  
E: tariqul@qsibd.com  
islamqshafique@gmail.com

#### PALTAN BRANCH UNIT-2

Paramount Heights (Level-9)  
65/2/1, Box Culvert Road,  
Purana Paltan, Dhaka-1000.  
T: Mobile: +8801819252604  
E: nasser@qsibd.com  
nasirhfc1986@gmail.com

<p>Revenue from Contracts with Customers. The Company has reported total revenue of TK. 410,102,396.</p> <p>The Company's primary customers are its corporate customer who are also entitled to get comparative rate of services invoiced.</p> <p>Given the significance and complexities involved in the accounting of Revenue, appropriate recognition of revenue has been considered as a key audit matter.</p>	<ul style="list-style-type: none"> <li>Assessed manual as well as application controls supporting revenue recognition.</li> <li>Assessed the invoicing and measurement systems up to entries in the general ledger.</li> <li>Examined customer invoices and receipts of payment on a test basis.</li> <li>Assessed the design of the processes set up to account for the transactions in accordance with the new standard.</li> <li>Assessed whether the sufficiency of disclosures as required by the new standard have been met.</li> <li>Assessed whether the sufficiency of disclosures as required to be made to opening balances due to the adoption of the new standard.</li> </ul>
<p><b>2. Valuation of Inventories</b></p> <p>Refer to note 06.00 to the financial statements.</p> <p>Inventories represent Tk. 444,095,853 of the Company; inventories are thus a material item to the financial statements.</p> <p>As described in the accounting policy note 2.11 to the financial statements, inventories are valued at the lower of cost or net realizable values. As such, management is required to make judgments in determining whether inventories are being appropriately valued. Volume of inventories being held by the company at the reporting date and the complexities involved in the accounting and presentation thereof, Inventories has been considered as a key audit matter.</p>	<p>In order to test the Inventories, we performed the following procedures;</p> <ul style="list-style-type: none"> <li>Tested the operating effectiveness of key controls over Inventories; including observing the process of management's Year-end inventory count.</li> <li>Verified a sample basis the net realizable value by comparing costs to recent selling prices and assessing the reasonableness of any resulting write down of inventory items.</li> <li>Performed cut-off tests to determine that the purchases and sales of the inventories have been captured in the correct accounting period.</li> <li>Reviewed the historical accuracy of inventory provisions and the level of write-downs.</li> </ul>
<p><b>3. Recovery of Trade Receivables</b></p> <p>Refer to note 7.00 to the financial statements Trade Receivables represent amount TK. 419,594,428 as at 30 June 2024 of the Company.</p> <p>The recoverability of trade receivables is considered to be a key risk due to the significance of these balances to the financial statements, and the judgments required in making appropriate provisions.</p>	<p>In order to test the recoverability of trade receivables, we performed the following procedures:</p> <ul style="list-style-type: none"> <li>We evaluated the company's credit control procedures and assessed and validated the ageing profile of Trade Receivables.</li> <li>We assessed recoverability on a sample basis by reference to cash received subsequent to year-end, agreement to the terms of the contract in place, and issue of credit notes post year-end, as necessary;</li> </ul> <p>We communicate management as to the recoverability of the older, unprovided amounts, corroborating management's explanations with underlying documentation and correspondence with the customers.</p>

4.	<p><b>Property, Plant and Equipment (PPE)</b></p> <p>As refer to notes 03.00 to the financial statements Property, Plant and Equipment includes the company's long-term assets, which flow economic benefits to the entities more than one year. PPE is measured at cost less accumulated depreciation. The carrying value of PPE represents significant portion of total assets, which is amounting to Tk. 1,629,983,446 for the company at the reporting date.</p> <p>The carrying value of PPE is include asset addition during the year is Tk. 131,121,028 the function of depreciation charges on cost that involved estimation. Therefore, it has been considered as significant area of auditor's judgement.</p>	<p>We have tested the design and operating effectiveness of key control over PPE. Our audit procedures included, among others, considering the impairment risk of the assets.</p> <p>Following are our audit procedures on the carrying value and impairment risk of PPE:</p> <ul style="list-style-type: none"> <li>• Reviewing basis of recognition, measurement of assets;</li> <li>• Observing procedures of assets acquisition, depreciation and disposal;</li> <li>• Checking ownership of the asset's addition;</li> <li>• Performing due physical asset verification on sample basis at the year-end;</li> <li>• Checking estimated rates of depreciation being used and assessed its fairness;</li> <li>• Evaluating the Company's assumption in relation to recoverable amounts of the major PPE to identify if there is any requirement of recognition of impairment; and</li> <li>• Finally, assessing the appropriateness and presentation of disclosures against relevant accounting standards.</li> </ul> <p>Our testing did not identify any issues with regard to Carrying Value of PPE.</p>
	<p><b>Deferred Tax</b></p> <p>The Company's report Net Deferred Tax Liability (DTL) totaling Tk. 153,713,545 as at 30 June, 2024.</p> <p>Significant judgment is required in relation to deferred tax liabilities as their recoverability is dependent on forecasts of future profitability over a number of years.</p> <p>The disclosures relating to Deferred Tax are included in note 15.00 to the financial statement</p>	<p>Our audit procedures are on as follows:</p> <ul style="list-style-type: none"> <li>• We obtained an understanding, evaluates the design and tested the operational effectiveness of the Institution's key controls over the recognition and measurement of DTLs and the assumption used in estimating the Company's future taxable income.</li> <li>• We also assessed the completeness and accuracy of the data used for the estimations of future taxable income.</li> <li>• We involved tax specialists to assess key assumption, controls, recognition and measurement of DTLs.</li> <li>• Finally assessed the appropriateness and presentation of disclosures against "IAS-12" Income Tax.</li> </ul>

**Information Other than the Financial Statement and Auditors Report Thereon**

Management is responsible for the other information. The other information comprises all of the information in the annual report other than the financial statements and our auditors' report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report.



Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

#### **Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls**

Management is responsible for the preparation and fair presentation of the financial statements of the Company in accordance with International Financial Reporting Standards (IFRSs) and the company Act 1994 and other applicable laws and regulations for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

#### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


From the matters communicates with those charged with governess, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### Report on other Legal and Regulatory Requirements

In accordance with the Companies Act, 1994 & the Securities and Exchange Rules 2020, Financial Reporting Act-2015, we also report that:

- (i) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
- (ii) in our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books;
- (iii) the statement of financial position and statement of profit or loss and other comprehensive income together with the annexed notes dealt with by the report are in agreement with the books of account and returns;
- (iv) the expenditure incurred was for the purpose of the company's business.

Place: Dhaka  
Dated: October 31, 2024  
DVC: 2411030165AS865936

  
Quazi Shafiqul Islam, FCA  
Enrolment No. 0165  
Islam Quazi Shafique & Co.  
Chartered Accountants



**Silco Pharmaceuticals Limited**  
**Statement of Financial Position**  
As at June 30, 2024

Particulars	Notes	Amount in Taka	
		30 June 2024	30 June 2023
<b>Assets:</b>			
<b>Non Current Assets</b>		<b>1,767,324,096</b>	<b>1,762,417,380</b>
Property, Plant and Equipment	3.00	1,629,983,446	1,587,456,216
Right of Use Assets	4.00	9,244,529	-
Capital Work-in-Progress	5.00	128,096,122	174,961,164
<b>Current Assets</b>		<b>1,054,936,740</b>	<b>1,004,930,028</b>
Inventories	6.00	444,095,853	444,141,973
Trade and Other Receivables	7.00	419,594,428	377,507,323
Advances, Deposits and Prepayments	8.00	160,774,234	133,547,946
Cash and Cash Equivalents	9.00	28,699,542	30,764,262
Investment In Share	10.00	1,772,684	18,968,523
<b>Total Assets</b>		<b>2,822,260,837</b>	<b>2,767,347,407</b>
<b>Shareholder's Equity and Liabilities:</b>			
<b>Shareholder's Equity</b>		<b>2,352,439,767</b>	<b>2,319,852,389</b>
Share Capital	11.00	1,038,070,000	1,038,070,000
Retained Earnings	12.00	1,315,518,064	1,288,697,596
Unrealized Gain/Loss on Marketable Securities	13.00	(1,148,297)	(6,915,207)
<b>Non-Current Liabilities</b>		<b>159,021,936</b>	<b>151,734,305</b>
Lease Liabilities (Non Current Portion)	14.00	5,308,391	-
Deferred Tax Liabilities	15.00	153,713,545	151,734,305
<b>Current Liabilities</b>		<b>310,799,133</b>	<b>295,760,714</b>
Trade and Other Payable	16.00	9,604,865	9,749,939
Lease Liabilities (Current Portion)		4,258,996	-
Payable to IPO Applicants	17.00	184,493	184,607
Provision for Expenses	18.00	6,273,320	6,322,574
Liabilities for contribution to WPPF	19.00	2,906,798	3,342,966
Dividend Payables (Unclaimed)	20.00	2,377,502	2,458,950
Provision for income tax	21.00	285,193,159	273,701,678
<b>Total Shareholder's Equity and Liabilities</b>		<b>2,822,260,837</b>	<b>2,767,347,407</b>
<b>Net Asset Value (NAV) per Share</b>	30.00	<b>22.66</b>	<b>22.35</b>

The annexed notes are (1-41) form an integral part of these financial statements.

নাসিম জাভেদ  
Chairman

  
Managing Director

  
Company Secretary

Signed as per our separate report on same date.

Place: Dhaka  
Date: 31 October 2024  
DVC: 2411030165AS865936

  
Quazi Shafiqul Islam, FCA  
Enrolment No. 0165  
Islam Quazi Shafique & Co.  
Chartered Accountants





**Silco Pharmaceuticals Limited**  
**Statement of Profit or Loss and other Comprehensive Income**  
For the year ended June 30, 2024

Particulars	Notes	Amount in Taka	
		2023-2024	2022-20223
Turnover			
Less: Cost of Goods Sold	22.00	410,102,396	464,695,705
Gross Profit /(Loss)	23.00	277,862,012	318,389,658
		<b>132,240,384</b>	<b>146,306,046</b>
Less: Operating Expenses	24.00	70,160,303	75,782,467
Profit from Operation		<b>62,080,081</b>	<b>70,523,580</b>
Less: Financial Expenses	25.00	110,663	126,299
Less: Financial Expenses (Lease)	26.00	926,653	195,000
Non-operation Income	27.00	1,213,812	22,384,901
Profit before Contribution to WPPF		<b>62,256,577</b>	<b>92,587,183</b>
Less: Workers' Profit Participation/Welfare Fund (WPPF)	19.01	2,906,798	3,342,966
Profit before Income Tax		<b>59,349,778</b>	<b>89,244,217</b>
Less: Provision for Income Tax	28.00	13,470,721	20,022,933
Current Tax	28.01	11,491,480	18,495,881
Deferred Tax	28.02	1,979,240	1,527,052
Net Profit/(Loss) after Tax (Transferred to Retained Earning )		<b>45,879,058</b>	<b>69,221,284</b>
Other Comprehensive Income:			
Unrealized Gain/(Loss) on Investment	13.00	5,766,910	3,772,085
Total Comprehensive income		<b>51,645,968</b>	<b>72,993,369</b>
Earnings per Share (EPS)	29.00	<b>0.44</b>	<b>0.67</b>

The annexed notes are (1-41) form an integral part of these financial statements.

মাহমুদ কামাল  
Chairman

  
Managing Director

  
Company Secretary

Signed as per our separate report on same date.

Place: Dhaka  
Date: 31 October 2024  
DVC: 2411030165A5865936

  
Quazi Shafiqul Islam, FCA  
Enrolment No. 0165  
Islam Quazi Shafique & Co.  
Chartered Accountants



**Silco Pharmaceuticals Limited**  
**Statement of Changes in Equity**  
For the year ended June 30, 2024

Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2023	1,038,070,000	(6,915,207)	1,288,697,596	2,319,852,389
Net Profit/(Loss) during the year	-	-	45,879,058	45,879,058
Declared 3% Cash Dividend			(19,058,589)	(19,058,589)
Unrealized Gain/(Loss) on Marketable Shares	-	5,766,910		5,766,910
<b>Balance as on June 30, 2024</b>	<b>1,038,070,000</b>	<b>(1,148,297)</b>	<b>1,315,518,065</b>	<b>2,352,439,767</b>

**Statement of Changes in Equity**  
For the year ended June 30, 2023

Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2022	1,038,070,000	(10,687,292)	1,251,240,627	2,278,623,335
Net Profit/(Loss) during the year	-	-	69,221,284	69,221,284
Declared 5% Cash Dividend			(31,764,315)	(31,764,315)
Unrealized Gain/Loss on Marketable	-	3,772,085		3,772,085
<b>Balance as on June 30, 2023</b>	<b>1,038,070,000</b>	<b>(6,915,207)</b>	<b>1,288,697,596</b>	<b>2,319,852,389</b>

নাসিম জাহাঙ্গীর  
Chairman

  
Managing Director

  
Company Secretary



**Silco Pharmaceuticals Limited**  
**Statement of Cash Flows**  
For the year ended June 30, 2024

Particulars	Notes	Amount in Taka	
		2023-2024	2022-2023
<b>A. Cash Flows from Operating Activities</b>			
Cash received from Customers	34.00	368,015,291	476,424,842
Cash received from Non-operating Income		1,929,260	3,827,024
Cash Paid to Suppliers	35.00	(175,488,387)	(173,748,744)
Cash Paid to Employees	36.00	(64,297,925)	(65,710,185)
Cash Paid to Others	37.00	(39,007,064)	(53,192,103)
Financial Expenses		(110,663)	(126,299)
Income Tax Paid		(6,730,339)	(6,993,151)
<b>Net cash flows from operating activities</b>		<b>84,310,173</b>	<b>180,481,383</b>
<b>B. Cash Flows from Investing Activities</b>			
Acquisition of Property, Plant & Equipment		(7,526,900)	(2,980,960)
Cash Payment for Capital Work-in-Progress		(76,729,086)	(178,968,121)
Gain/(Loss) on Investment		(715,448)	18,557,877
Investment in Share		22,962,750	22,709,859
<b>Net cash used in investing activities</b>		<b>(62,008,684)</b>	<b>(140,681,344)</b>
<b>C. Cash Flows from Financing Activities</b>			
Refund to IPO Applicants (Bank Charge)		(114)	(121)
Financial Expenses (Lease)		(926,653)	(195,000)
Principle payment (Lease)		(4,299,407)	(4,112,544)
Cash dividend paid		(19,140,036)	(31,447,372)
<b>Net Cash used for financing activities</b>		<b>(24,366,210)</b>	<b>(35,755,036)</b>
<b>D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)</b>		<b>(2,064,721)</b>	<b>4,045,004</b>
<b>E. Cash and Cash Equivalents at the beginning of the year</b>		<b>30,764,262</b>	<b>26,719,260</b>
<b>F. Cash and Cash Equivalents at the end of the year (D+E)</b>		<b>28,699,542</b>	<b>30,764,262</b>
<b>Net Operating Cash Flows Per Share (NOCFPS)</b>	31.00	<b>0.81</b>	<b>1.74</b>

নারীম আলী  
Chairman

  
Managing Director

  
Company Secretary



**Silco Pharmaceuticals Limited**  
**As at and for the year ended 30 June 2024**  
Notes, Comprising A Summary of Significant Accounting Policy  
And Other Explanatory Information

**1.00 The Company and its operations**

**1.01 Legal form of the Company**

The Company was incorporated in Bangladesh as Public Limited Company on January 25, 1995 as Company limited by Shares under the Companies Act 1994 vide registration no. C-27781(1627)/95. The principal activities of the Company are manufacturing drugs and medicines of all kinds. The Company obtained Certificate of Commencement of business at the same date of incorporation but the Company received its drug manufacturing license on 29<sup>th</sup> October, 2003 and the commercial operation started on 30<sup>th</sup> October, 2003. The company listed with Dhaka and Chittagong stock exchange on 25<sup>th</sup> April 2019 & 30<sup>th</sup> April 2019.

**1.02 Address of the Registered Office**

The registered office of the company is located at 41, Nurani, Bankalapara, Subid Bazar, Sylhet-3100, Bangladesh.

**1.03 Nature of Business activities**

Silco Pharmaceuticals limited has engaged in manufacturing and marketing of pharmaceuticals finished product in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Antipyretics, Anti In Flammatory Drugs, Anti ulcerants, Multi medicines which are sold in local market and in international markets respectively.

**1.04 Capital Structure of the Company**

Silco Pharmaceuticals Limited is a public limited company formed by local owner. The details of the capital structure are given below:

Particulars	Taka
<b>Authorized Capital</b> 105,000,000 ordinary shares of Taka 10/= each.	1,050,000,000
<b>Issued, subscribed, called-up and paid-up capital</b> 103,807,000 ordinary shares of Tk. 10/= each fully paid-up	1,038,070,000

**1.05 Production Unit**

The production unit of the company is situated at BSCIC industrial Estate, Khadimnagar, Sylhet 3103, Bangladesh.

**2.00 Summary of significant accounting policies as per rules**

**2.01 Basis of preparation and presentation of the financial statements**

The financial statements have been prepared on a going concern basis under historical cost convention and in accordance with the International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs), the Companies Act, 1994, the Securities and Exchange Rules,



2020 and other applicable laws & regulations in Bangladesh. The Financial Statements are presented in accordance with the guidelines provided by IAS-1 "Presentation of Financial Statements".

**2.02 Regulatory Compliances**

As required by the company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

The Income Tax Act 2023;

The Value Added Tax and Supplementary Duty Act 2012;

The Value Added Tax and Supplementary Duty Rules 2016;

The Customs Act, 1969;

Bangladesh Labour Act 2006 (Amendment-2013);

The Securities and Exchange Ordinance, 1969;

The Securities and Exchange Rules, 2020; and

Financial Reporting Act 2015.

**2.03 Accounting convention and assumption**

The financial statements are prepared under the historical cost convention.

**2.04 Principal accounting policies**

The specific accounting policies have been selected and applied by the Company's management for significant transactions and events that have a material effect within the Framework of IAS-1 "Presentation of Financial Statements" in preparation and presentation of the financial statements. Financial Statements have been prepared and presented in compliance with applicable IAS and IFRS.

**2.05 Application of Standards (IASs and IFRSs)**

The following IASs and IFRSs are applicable for preparation of financial statements for the year ended 30 June 2024.

**IASs:**

IAS 1	Presentation of Financial Statements;
IAS 2	Inventories;
IAS 7	Statement of Cash Flows;
IAS-8	Accounting Policies, Changes in Accounting Estimates and Errors;
IAS 10	Events after the reporting Period;
IAS 12	Income Taxes;
IAS 16	Properties, Plant and Equipment;
IAS 19	Employee Benefits;
IAS 21	The Effects of Changes in Foreign Exchange Rates;
IAS 23	Borrowing Costs;
IAS 24	Related Party Disclosures;
IAS 33	Earnings per Share;
IAS 36	Impairment of Assets;
IAS 37	Provisions, Contingent Liabilities and Contingent Assets;

**IFRSs:**

IFRS 1	First time Adoption of International Financial Reporting Standards;
IFRS 8	Operating Segments;
IFRS 9	Financial Instruments;
IFRS 13	Fair Value Measurement;
IFRS 15	Revenue from Contracts with Customers;
IFRS 16	Leases;

**2.06 Use of Estimates and Judgments**

The preparation of the financial statements requires management to make and apply consistently of judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates and underlying assumptions, which are reviewed on an ongoing basis. Revision to accounting estimates is recognized in the year in which the estimates are revised and in any future years affected.

**2.07 Re-arrangement**

Figures for the comparative year have been re-arranged wherever consider necessary to ensure better comparability with the current year presentation as per IAS-8 "Accounting policies, changes in Accounting estimates and Errors".

**2.08 Going Concern**

The company has adequate resources to continue in operation for foreseeable future and hence, the financial statements have been prepared on going concern basis. As per management assessment there is no material uncertainties related to event or condition which may cast significant doubt upon the company's ability to continue as a going concern.

**2.09 Components of the Financial Statements**

According to the IAS-1 "Presentation of Financial Statements" the complete set of financial statements includes the following components:

- i) Statement of Financial Position as at June 30, 2024
- ii) Statement of Profit or Loss and other Comprehensive Income for the year ended June 30, 2024;
- iii) Statement of Changes in Equity for the year ended June 30, 2024;
- iv) Statement of Cash Flows for the year ended June 30, 2024; and
- v) Notes, comprising a summary of significant accounting policy and other explanatory information for the year ended June 30, 2024.

**2.10 Property, Plant and Equipment (PPE)**

**i) Recognition and Measurement**

In compliance with the IAS 16 "Property, Plant and Equipment" items of Property, Plant & Equipment (PPE) excluding Land and Land Development are initially measured at cost less accumulated depreciation, if any. Land and Land Development are measured at cost. The cost of an item of PPE comprises its purchase price, import duties and non-refundable taxes after deducting

trade discount and rebates and any costs directly attributable to bringing the assets to the location and condition necessary for it to be capable operating in the intended manner.

**ii) Subsequent Cost**

The cost of replacing part of an item of property, plant & equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the company and its cost can be measured reliably. The cost of the day to day maintaining cost on PPE is recognized in the Statement of Profit or Loss and Other Comprehensive Income as incurred.

**iii) Depreciation**

Depreciation has been charged on item of property, plant and equipment except land and land development is recognized in the statement of profit or loss and other comprehensive income using "Reducing Balance Method" over the estimated useful lives of each items. Depreciation on addition to fixed assets charged when the assets are available for use i.e. when it is in the location and condition necessary for it to be capable of operating in the manner intended by the management.

Rate of depreciation on property, plant and equipment's considering their useful lives are as follows:

Category of Fixed Assets	As at 30 June, 2024	As at 30 June, 2023
Land and Land Development	-	-
Building	2.50%	2.50%
Plant & Machinery	10%	10%
Electrical Equipment	10%	10%
Electrical Installation	10%	10%
Furniture & Fixture	10%	10%
Office Equipment	10%	10%
Computer	20%	20%
Transformer	10%	10%
Vehicles	10%	10%
Air Condition	20%	20%
Fire Extinguisher	20%	20%

**iv) Retirement and Disposals:**

An asset is derecognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gain or loss arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized as gain or loss from disposal of asset under other income in the statement of comprehensive income.

**v) Impairment:**

In accordance with the provision of IAS 36, the carrying amount of non-financial assets other than inventories of the company involved in the manufacturing of the products. If any such indication

exists, then the asset's recoverable amount is estimated and impairment losses are recognized in the statement of comprehensive income. No such indication of impairment has been observed till the end of the year.

#### 2.11 Valuation of Inventory

Inventories consisting of raw materials, work in process, finished goods are valued at lower of cost and net realizable value as per IAS 2: Inventory. Cost of inventories include expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Cost of inventories is determined by using the weighted average cost formula. Where necessary, allowance is provided for damaged, obsolete and slow-moving items to adjust the carrying amount of inventories to the lower of cost and net realizable value. Net realizable value is based on estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

#### 2.12 Trade and Other Receivables

Trade Receivable is carried at net sales value by making no provision for doubtful debts, based on the risk from time to time. But in case of any debts made with any dissolved business house, the amount is fixed and charged with profit and loss account.

#### 2.13 Cash and cash equivalents

Cash and cash equivalents include cash in hand, cash at banks, term deposits, etc which are available for use by the company without any restrictions. There is an insignificant risk of change in value of the same.

#### 2.14 Creditors and accrued expenses

##### i) Trade payables

Liabilities are recorded at the amount payable for settlement in respect of goods and services received by the company.

##### ii) Provision

The preparation of financial statements in conformity with International Accounting Standard IAS-37 "Provisions, Contingent Liabilities and Contingent Assets" requires management to make estimates and Assumption that affect the reported amounts of revenues and expenses, assets and liabilities, and the Disclosure requirements for contingent assets and liabilities during and at the date of the financial statements.

In accordance with the guidelines as prescribed by IAS-37 provisions were recognized in the following situations when:

- The Company has a present obligation as a result of past event;
- It is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and
- When reliable estimates can be made of the amount of the obligation.

We have shown the provisions of the Financial Position at an appropriate level with regard to an adequate provision for risks and uncertainties. An amount recorded as a provision represents the best estimate of the probable expenditure required to fulfill the current obligation on the date of statement of financial position.





## 2.15 Employee benefits

The company maintains both defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds.

The company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19 Employee Benefits.

The cost of employee benefits is charged as revenue expenditure in the period to which the contributions relate.

The company's employee benefits include the following:

### (a) Short-term employee benefits

Short-term employee benefits include salaries, bonuses, house rent, medical fees etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

### (b) Contribution to Workers' Profit Participation/ Welfare Funds

The company provisions 5% of its profit from net business income to its Workers' Profit Participation Fund (WPPF) in accordance with Bangladesh Labour Act 2006 (Amendment-2013). The Company has registered the WPPF Trust deed and disbursed the provisioned amount accordingly.

The company made provision for WPPF in line with section 234 (a) chapter-XV (Workers' participation in Companies Profits) of Bangladesh Labour Act-2006 and complied with section 234 (b). Transfer of the amount to a separate bank account is under process. The management of the company tried to disburse the amount to workers through banking channel but in fact, it was very hard to find a separate bank account of all the workers. Considering circumstance and requirement for compliance with chapter-XV section 234 (a) & (b) of Bangladesh Labour Act-2006,

It was hard for the management to ensure bank accounts of all workers who belongs to marginal class of the society. The payment of WPPF was made in cash. The company had also made the contribution to 'Bangladesh Labour welfare Foundation' through designated government as per requirement of Bangladesh Labour Act-2006.

## 2.16 Income Tax

### i) Current Tax

Provision for taxation has been made as per rates prescribed in Finance Act 2024 and the Income Tax Act, 2023 on the profit made by the company.

### ii) Deferred Tax

The company has recognized deferred tax in compliance with the provision of IAS-12: "Income Taxes". The policy of recognition of deferred tax assets/liabilities is based on temporary differences (taxable or deductible) between the carrying amount (Book Value) of assets and liabilities for financial reporting purpose and its tax base, and accordingly, deferred tax income or expense has

been considered to determine net profit after tax. The rate prevailing at the Financial Position date is used for determine the deferred tax.

The company assumes no other temporary difference that may result in deferred tax asset/liability except Property, plant and Equipment.

**2.17 VAT**

Company's Produces both Vatable and Non-Vatable Product. The company paid VAT only on vatable items and enjoying exemption for non-vatable items as per S.R.O No. 163-Law/2022/176-VAT, dated: June 01, 2022.

**2.18 Contingent liabilities and assets**

Contingent liabilities and assets are current or possible obligations or assets, arising from past events and whose existence is due to the occurrence or non-occurrence of one or more uncertain future events which are not within the control of the company. In accordance with IAS-37 "Provisions, Contingent Liabilities and Contingent Assets" should not be recognized in the year in which the recognition criteria of provision have been made.

**2.19 Revenue recognition**

"As per IFRS-15: "Revenue from Contracts with Customers" an entity shall account for a contract with a customer only when all of the following criteria are met:

- a) The parties to the contract have approved the contract (in writing, orally or in accordance with other customary business practices) and are committed to performing their respective obligations;
- b) The entity can identify each party 's rights regarding the goods or services to be transferred;
- c) The entity can identify the payment terms for the goods or services to be transferred;
- d) The contract has commercial substance (i.e. the risk, timing or amount of the entity's future cash flows is expected to change as a result of the contract); and
- e) It is probable that the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer."

Considering the five steps model, the Company recognizes revenue at the time of delivery when (or as) the Company satisfies a performance obligation by transferring a promised good to a customer. Goods are considered as transferred when (or as) the customer obtains control of those goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net of returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

**Sale of goods**

The revenue from the sale of goods is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer when the buyer provides assurance on the delivery of goods. The revenue represents the invoice value of goods supplied to the customers measured at the fair value of the consideration received or receivable.

**2.20 Borrowing costs**

In compliance with the requirements of IAS-23 "Borrowing Costs" borrowing costs of operational year on long term loan and short-term loan facilities from bank was charged off as revenue expenditure as they incurred.

**2.21 Repairs, upkeep and maintenance charges**

These are usually charged out as revenue expenditure in the year in which it is incurred.

**2.22 Related party disclosure**

The company in normal course of business carried out a number of transactions with related parties that fall within the definition of related party as prescribed by IAS-24 "Related Party Disclosures". This has been disclosed in a separate note to the financial statements.

**2.23 Earnings per Share (EPS)**

The Company calculates its Earning per Share (EPS) in accordance with IAS 33 "Earnings per Share" which has been shown on the face of Statement of Comprehensive Income and the computation of EPS.

**Basic Earnings**

This represents earnings for the period attributable to the ordinary shareholders. As there are no preference dividends, minority interest or extra ordinary items, the net profit for the year has been considered as fully attributable to ordinary shareholders.

**Basic Earnings Per Share**

Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the company by the weighted average number of ordinary shares outstanding during the year.

**Diluted Earnings per Share**

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and weighted average number of ordinary shares outstanding, for the effect of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these Financial Statements as there were no potential ordinary shares during the relevant year.

**Weighted Average Number of Ordinary Shares outstanding during the year**

The basis of computation of number of shares in line with the provisions of IAS-33: Earnings per share. Therefore, the total number of shares outstanding at the year multiplied by a time-weighting factor which is the number of days the specific shares were outstanding as proportion of total number of days in the year.

**2.25 Date of Authorization**

The Board of Directors of Silco Pharmaceuticals Limited approved this Financial Statements on 31 October 2024.

**2.26 Segment Reporting**

As required by IFRS-8 "Operating Segments", if an entity operates and engages in different economic environments and activities then the entity has to disclose information, to enable users of its financial statements to evaluate the nature and financial effects of the business so carried out.

The company considers the operation on aggregate basis and manages the operations as a single operating segment. Hence it is felt that such segment reporting is not required to be disclosed.

**2.27 Statement of Cash flows**

Statement of Cash Flows is prepared principally in accordance with IAS-7 "Statement of Cash Flows" and the cash flows from the operating activities have been presented under direct method as prescribed by the Securities and Exchange Rules 2020 and considering the provision of paragraph 19 of IAS-7 which provides that "Enterprises are Encouraged to Report Cash Flows from Operating Activities Using the Direct Method". We also provide cash flows from operating activities using the Indirect Method as well in notes to the Financial Statements.

**2.28 Reporting period**

The financial period of the Company covers 1 (one) year from 1<sup>st</sup> July 2023 to 30<sup>th</sup> June 2024.

**2.29 Events after the Reporting period**

In compliance with the requirements of IAS 10 Events after the Reporting Period that provide additional information about the company's position at the date of the financial position are reflected in the financial statements and events after the reporting period that are not adjusting events are disclosed in the notes when materials.

Management of the company has taken close look whether any events after the reporting period exist that need to take into account during the preparation of Financial Reports. No event after the reporting period exists and management of the company has prepared the financial reports in accordance.

**2.30 Financial Risk Management Policies**

The company is exposed to normal business risks from changes in market interest rates and currency exchange rates and from non-performance of contractual obligations by counterparties. The company does not hold or issue derivative financial instruments for speculative or trading purposes.

**Interest Rate Risk**

The company has no significant risk of fluctuations in interest rates.

**Credit Risk**

Credit risk is the potential financial loss resulting from the failure of a customer or counterparty to settle its financial and contractual obligations to the company as and when they fall due.

Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis. Credit evaluations are performed on all customers requiring credit over a certain amount. At the reporting date there were no significant concentrations of credit risk. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the statement of financial position. However, due to the large number of parties comprising the group's customer base, Management does not anticipate material losses from its debt collection.

**Liquidity Risk**

The company monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by management to finance the company operations and to mitigate the effects of fluctuations in cash flows.

**Fair Values**

The fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction.

The fair value of trade and other short-term receivables are taken to approximate their carrying value. The fair value of financial assets and liabilities approximate their carrying value.

**2.31 Capital Work in Progress**

Property, plant and equipment under construction/ acquisition are accounted for as capital work-in-progress until construction/ acquisition is complete and measured at cost. As the capital work

in progress has not yet been finished and is not contributing to the production process to generate revenue, depreciation is not applied for capital work in progress as per Generally Accepted Accounting Principles (GAAPs- revenue and expense recognition principle).

## 2.32 Significant accounting policies

### (i) Financial Instruments

At initial recognition as per IFRS-9 Financial Instrument, an entity shall measure a financial asset or financial liability as its fair value plus or minus (in the case of a financial asset or a financial liability not at fair value through profit or loss) the transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability.

After initial recognition (subsequent measurement) an entity shall measure a financial asset or financial liability in either of the following subject to specific circumstance specified in the standard (sec 4.1.1- 4.1.5) & (4.2.1-4.2.2):

- i. amortized cost;
- ii. fair value through other comprehensive income;
- iii. fair value through profit or loss.

The entity shall recognize loss allowance or Expected Credit Loss (impairment requirement). At each reporting date the entity account for the impairment of financial assets or financial liability in the following manner:

- I. an amount equal to the lifetime expected credit loss (if the credit risk of the instrument has increased significantly since initial recognition)
- II. an amount equal to the 12 (twelve) month expected credit loss (if the credit risk of the instrument has not increased significantly since initial recognition)

### (ii) Leases

An entity shall assess a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In line with IFRS-16 Leases, an entity shall determine the lease term as the non-cancellable period of a lease together with both:

- I. Period covered by the option to extend the lease and;
- II. Period covered by the option to terminate the lease.

Initial measurement of right of use asset shall be measured at cost and subsequently either by fair value or follow revaluation model.

The company disclosed the impact of IFRS-16 of numerical amount and disclosures in the financial statement in Annexure-B.

### (iii) Insurance Contracts

IFRS 17 was issued in May 2017 and applies to annual reporting periods beginning on or after 1<sup>st</sup> January 2021. IFRS 17 established the principles for the recognition, measurement, presentation and disclosure of insurance contracts within the scope of the standard. The objective of IFRS 17 is to ensure that an entity provides relevant information that faithfully represents those contracts.

The company has not yet assessed in potential impact of IFRS 17 on its financial statements.

## 2.33 Bad and Doubtful Debts

The Management recognized the bad and doubtful debts when a debt is unrecoverable through Board of Directors approved. Since, the management made sales through 100% confirms order by the customers and duly collected by the marketing team. Hence, no bad debts had occurred and therefore no provision was made against the receivables.

**2.34 Implication of COVID-19 on our business**

The COVID-19 pandemic has developed rapidly in 2020 leaving its trail till June, 2024. The company managed to overcome the situation. The management has taken required steps to restore regular production capacity and sales considering the health and safety issues.

COVID-19 is not expected to have a significant impact on the entity. Management has determined that there is no material uncertainty that casts doubt on the entity's ability to continue as a going concern. There exists stable growth of the financial indicators of the company.

**2.35 General**

- i. Wherever considered necessary, previous period's figures have been rearranged for the purpose of comparison.

Previous year's figure has been rearranged wherever considered necessary to confirm to current year's presentation.



Notes No.	Particulars	Amount in Taka	
		30 June 2024	30 June 2023
<b>3.00</b>	<b>Property, Plant and Equipment</b>		
	Opening Balance	2,602,219,270	2,397,848,928
	Add: Addition during the year	131,121,028	204,370,342
	<b>Closing Balance</b>	<b>2,733,340,298</b>	<b>2,602,219,270</b>
	Opening Balance	1,014,763,054	928,045,265
	Add: Depreciation Charged for the year	88,593,798	86,717,788
	<b>Closing Balance</b>	<b>1,103,356,852</b>	<b>1,014,763,054</b>
	<b>Written Down Value as at June 30, 2024</b>	<b>1,629,983,446</b>	<b>1,587,456,216</b>

The details of above has been shown in "Annexure- A"

<b>4.00</b>	<b>Right of Use Assets</b>		
	Opening Balance	11,429,609	11,429,609
	Add: Addition during the year	13,866,793	-
	Less: Disposal during the year	11,429,609	-
	<b>Closing Balance</b>	<b>13,866,793</b>	<b>11,429,609</b>
	Opening Balance	11,429,609	7,619,740
	Add: Amortization/ Depreciation Charged for the year	4,622,264	3,809,870
	Less: Disposal during the year	11,429,609	-
	<b>Closing Balance</b>	<b>4,622,264</b>	<b>11,429,609</b>
	<b>Written Down Value as at June 30, 2024</b>	<b>9,244,529</b>	<b>-</b>

The details of above has been shown in "Annexure- B"

<b>5.00</b>	<b>Capital Work-in -Progress</b>		
	Construction of Building	5.01 74,207,645	119,786,023
	Plant and Machinery	5.02 53,888,476	55,175,140
	<b>Total</b>	<b>128,096,122</b>	<b>174,961,164</b>
<b>5.01</b>	<b>Construction of Building</b>		
	Opening Balance	119,786,023	170,646,389
	Add: Addition during the year	33,479,318	72,631,574
		<b>153,265,341</b>	<b>243,277,962</b>
	Less: Transfer to fixed assets during the year	79,057,696	123,491,939
	<b>Closing Balance</b>	<b>74,207,645</b>	<b>119,786,023</b>

Notes No.	Particulars	Amount in Taka	
		30 June 2024	30 June 2023
<b>5.02</b>	<b>Plant and Machinery</b>		
	Opening Balance	55,175,140	26,736,036
	Add: Addition during the year	43,249,768	106,336,547
		<b>98,424,908</b>	<b>133,072,583</b>
	Less: Transfer to fixed assets during the year	44,536,432	77,897,443
	Closing Balance	<b>53,888,476</b>	<b>55,175,140</b>
<b>6.00</b>	<b>Inventories</b>		
	Raw Materials 23.01	193,065,890	189,799,690
	Packaging Materials 23.02	14,958,695	19,283,993
	Work in Process 23.00	9,591,022	9,821,785
	Finished Goods 23.00	220,525,748	219,229,298
	Store Items 23.03.01	5,954,498	6,007,206
	<b>Total</b>	<b>444,095,853</b>	<b>444,141,973</b>
<b>7.00</b>	<b>Trade and Other Receivables</b>		
	Trade Receivables	419,594,428	377,507,323
	<b>Total</b>	<b>419,594,428</b>	<b>377,507,323</b>
	<b>Ageing of the above Trade Receivable is given below:</b>		
	Less than twelve months	66,419,300	43,215,740
	Less than six months	353,175,128	334,291,583
	<b>Total</b>	<b>419,594,428</b>	<b>377,507,323</b>

The classification of receivables as required by the schedule XI of the Companies Act, 1994 are given below:

i. Receivables considered good in respect of which the company is fully secured		
ii. Receivables considered good in respect of which the company holds no security other than the debtor personal security	419,594,428	377,507,323
iii. Receivables considered doubtful or bad		
iv. Advance, deposits & prepayment due by directors or other officers of the company or any of them either severally or jointly with any other person or Advance, deposits & prepayment due by firms or private companies respectively in which any director is a partner or a director or a member		
v. Receivables due from companies under same management		
vi. The maximum amount of receivable due by any director or other officer of the company		



Notes No.	Particulars	Amount in Taka		
		30 June 2024	30 June 2023	
<b>8.00</b>	<b>Advances, Deposits and Prepayments</b>			
	Advances	8.01	158,612,407	131,971,119
	Deposits	8.02	1,576,827	1,576,827
	Prepayments	8.03	585,000	-
	<b>Total</b>		<b>160,774,234</b>	<b>133,547,946</b>
<b>8.01</b>	<b>Advances</b>			
	Advance to Employees		778,800	826,500
	Advance to Suppliers		78,541,869	59,887,100
	Advance Income Tax L/C Margin	08.01.01	77,878,296	71,147,957
	VAT Current A/C.		1,237,000	-
	<b>Total</b>		<b>158,612,407</b>	<b>131,971,119</b>
<b>08.01.01</b>	<b>Advance Income Tax (AIT)</b>			
	Opening Balance		71,147,957	64,154,806
	AIT Paid during the year		6,730,339	6,993,151
	<b>Closing Balance</b>		<b>77,878,296</b>	<b>71,147,957</b>
<b>8.02</b>	<b>Security Deposit</b>			
	Electricity (Power Development Board)		317,400	317,400
	Gas (Jalalabad Gas Distribution Company Ltd.)		1,259,427	1,259,427
	<b>Total</b>		<b>1,576,827</b>	<b>1,576,827</b>
<b>8.03</b>	<b>Prepayments</b>			
	Office Rent		585,000	-
	<b>Total</b>		<b>585,000</b>	<b>-</b>
<b>9.00</b>	<b>Cash and Cash Equivalent</b>			
	Cash in hand		10,498,678	7,800,093
	Cash at Bank	9.01	18,200,864	22,964,169
	<b>Total</b>		<b>28,699,542</b>	<b>30,764,262</b>
<b>9.01</b>	<b>Cash at Bank</b>			
	Cash at Bank	09.01.01	17,974,024	15,861,101
	IPO Fund	09.01.02	217,644	217,840
	Balance of Portfolio	09.01.03	9,196	6,885,228
	<b>Total</b>		<b>18,200,864</b>	<b>22,964,169</b>

Notes No.	Particulars	Amount in Taka	
		30 June 2024	30 June 2023
<b>09.01.01</b>	<b>Cash at Bank</b>		
	Bank Asia CD # 01033005988	8,660,417	2,657,578
	City Bank Ltd., CD-3102434003001	2,357,878	2,434,706
	Bank Asia CD # 01036000766	2	76
	Pubali Bank Ltd., A/C No. C/D-2836901017223	862,671	939,189
	AB Bank Ltd., A/C No. C/D-4111-043420-000	143,341	88,708
	DBBL, A/C No. C/D-201.110.6703	281,724	349,640
	DBBL, A/C No. C/D-1881	212,524	858,882
	DBBL, A/C No. C/D-1154	94,985	5,985
	Pubali Bank Ltd., A/C No. C/D-3486901021357	2,617,405	6,156,521
	Prime Bank Ltd., A/C No. C/D-80025295/3115312009636	492,698	1,309,338
	Prime Bank Ltd., A/C No. C/D-60020426/3115111005507	2,174,780	1,059,157
	Al-Arafah Islami Bank A/c-20897	75,600	1,321
	<b>Total</b>	<b>17,974,024</b>	<b>15,861,101</b>
<b>09.01.02</b>	<b>IPO Fund</b>		
	EBL_ Principal Branch _BDT_A/C_1011360531186	33,151	33,233
	EBL_ Principal Branch_USD_A/C_1013050531221	149,984	150,098
	EBL_ Principal Branch_EURO_A/C_1013070531196	34,509	34,509
	<b>Total:</b>	<b>217,644</b>	<b>217,840</b>
<b>09.01.03</b>	<b>Balance of Portfolio</b>		
	AB Scurities Ltd.-Portfolio Code 08348	7,328	6,872,756
	City Brokerage Ltd.-Portfolio Code C12003	1,868	12,472
	<b>Total</b>	<b>9,196</b>	<b>6,885,228</b>
<b>10.00</b>	<b>Investment In Share</b>		
	FEDERALINS	-	7,507,504
	ORIONINFU	-	7,066,500
	MALEKSPIN	-	78,319
	KBPPWBIL	1,772,684	-
	PURABIGEN	-	3,340,200
	ASIA PACIFIC GICL	-	976,000
	<b>Total</b>	<b>1,772,684</b>	<b>18,968,523</b>

The Company recognised its investment considering fair value i. e. market value on 30 June, 2024.

Notes No.	Particulars	Amount in Taka	
		30 June 2024	30 June 2023
11.00	Share Capital		
11.01	Authorized Share Capital 105,000,000 ordinary shares of Tk. 10/= each.	<u>1,050,000,000</u>	<u>1,050,000,000</u>
11.02	Issued, Subscribed and Paid-up Share Capital 103,807,000 ordinary shares of Tk. 10/= each fully paid-up	<u>1,038,070,000</u>	<u>1,038,070,000</u>
		<u>1,038,070,000</u>	<u>1,038,070,000</u>

The shareholding position at the end of the year as on June 30, 2024 are shown below:

Category of Shareholders	No. of Ordinary Shares Held	Paid-up Capital (BDT)	Percentage (%) of Paid-up Capital
Directors, sponsor's & promoters	40,478,370	404,783,700	38.99%
Government	-	-	-
Institution	16,111,096	161,110,960	15.52%
Foreign	-	-	-
General Public	47,217,534	472,175,340	45.49%
<b>Total</b>	<b>103,807,000</b>	<b>1,038,070,000</b>	<b>100.00%</b>

The range of shareholdings are shown below:

SL No.	Shareholding Range	No. of Shareholders	No. of Shares	Percentage
1	Upto 100 Shares	619	24,455	0.02%
2	From 101 to 500 Shares	1,158	409,419	0.39%
3	From 501 to 1,000 Shares	1,390	1,079,696	1.04%
4	From 1,001 to 10,000 Shares	2,578	10,184,486	9.81%
5	From 10,001 to 20,000 Shares	406	5,951,692	5.73%
6	From 20,001 to 50,000 Shares	244	7,761,333	7.48%
7	From 50,001 to 1,00,000 Shares	94	7,365,121	7.10%
8	From 1,00,001 to 10,00,000 Shares	108	23,181,156	22.33%
9	From 10,00,001 to 50,00,000 Shares	10	27,968,099	26.94%
10	From 50,00,001 to 1,00,00,000 Shares	1	5,951,000	5.73%
11	From 1,00,00,001 and above Shares	1	13,930,543	13.42%
	<b>Total</b>	<b>6,609</b>	<b>103,807,000</b>	<b>100%</b>

12.00 Retained Earnings

Opening balance	1,288,697,596	1,251,240,627
Add: Profit during the year	45,879,058	69,221,284
	<b>1,334,576,653</b>	<b>1,320,461,911</b>
Less: Cash Dividend @3% for the year (2022-2023)	(19,058,589)	(31,764,315)
Closing Balance	<u>1,315,518,064</u>	<u>1,288,697,596</u>

Notes No.	Particulars	Amount in Taka	
		30 June 2024	30 June 2023
<b>13.00</b>	<b>Unrealized Gain/Loss on Marketable Securities</b>		
	Opening balance	(6,915,207)	(10,687,292)
	Add: Unrealized Gain/Loss on Marketable Shares	5,766,910	3,772,085
	<b>Closing Balance</b>	<b>(1,148,297)</b>	<b>(6,915,207)</b>
<b>14.00</b>	<b>Lease Liabilities</b>		
	Opening balance	-	4,112,546
	Add: Addition during the year (Principle)	13,866,793	-
	Add: Addition during the year (Interest)	926,653	195,000
	Less: Paid during the year	(5,226,060)	(4,307,544)
		<b>9,567,386</b>	-
	Less: Current Portion	4,258,996	-
	<b>Non- Current Portion</b>	<b>5,308,391</b>	-
<b>15.00</b>	<b>Deferred Tax Liabilities</b>		
	WDV as Accounting base (PPE)	1,629,983,446	1,587,456,216
	WDV as Accounting base (ROU)	9,244,529	-
	WDV as per Tax base (PPE)	(947,074,277)	(913,081,528)
	Lease Obligation*	(8,982,386)	-
	<b>Temporary Difference</b>	<b>683,171,312</b>	<b>674,374,689</b>
	Applicable Tax Rate	22.50%	22.50%
	<b>Deferred Tax Closing Balance</b>	<b>153,713,545</b>	<b>151,734,305</b>
	<b>*Lease Obligation</b>		
	Lease Liability as on 30 June 2024	9,567,386	-
	Less: Advance	(585,000)	-
	<b>Total</b>	<b>8,982,386</b>	-
<b>16.00</b>	<b>Trade and Other Payables</b>		
	Trade Payables	9,604,865	9,749,939
	<b>Total</b>	<b>9,604,865</b>	<b>9,749,939</b>
<b>17.00</b>	<b>Payable to IPO Applicants</b>		
	EBL_Principal Branch_USD_A/C_1013050531221	149,984	150,098
	EBL_Principal Branch_EURO_A/C_1013070531196	34,509	34,509
	<b>Total</b>	<b>184,493</b>	<b>184,607</b>
<b>18.00</b>	<b>Provision for Expenses</b>		
	Electricity, Gas, telephone, Water & other Bills	301,355	317,199
	Salary & Wages	5,511,965	5,145,135
	Director Remuneration	45,000	45,000
	Others	65,000	65,000
	TDS Payable	-	400,240
	Audit Fees	350,000	350,000
	<b>Total</b>	<b>6,273,320</b>	<b>6,322,574</b>

Notes No.	Particulars	Amount in Taka	
		30 June 2024	30 June 2023
<b>19.00</b>	<b>Liabilities for contribution to WPPF</b>		
	Opening Balance		
	Add: Addition during the year	3,342,966	9,929,514
	Available for contribution to WPPF	2,906,798	3,342,966
	Less: Paid during the year	6,249,764	13,272,480
	Closing Balance	3,342,966	9,929,514
		<u>2,906,798</u>	<u>3,342,966</u>
<b>19.01</b>	<b>Provision for WPPF during the year</b>		
	Profit before Contribution to WPPF	62,256,577	92,587,183
	Less: Non-operation Income (Net)	1,213,812	22,384,901
	Provision during the year	61,042,765	70,202,281
		<u>2,906,798</u>	<u>3,342,966</u>
<b>20.00</b>	<b>Dividend Payables (Unclaimed)</b>		
	Opening Balance	2,458,950	2,142,006
	Add: Addition during the year	19,058,589	31,764,315
		21,517,539	33,906,321
	Less: Paid during the year	19,140,036	31,447,372
	Closing Balance	2,377,502	2,458,950
		<u>2,377,502</u>	<u>2,458,950</u>
<b>21.00</b>	<b>Provision for income tax</b>		
	Opening Balance	273,701,678	255,205,797
	Add: Charge for the year	11,491,480	18,495,881
	Closing Balance	285,193,159	273,701,678
		<u>285,193,159</u>	<u>273,701,678</u>

Notes No.	Particulars	Amount in Taka	
		2023-2024	2022-2023
<b>22.00</b>	<b>Turnover</b>		
	Sales	410,102,396	464,695,705
	<b>Total</b>	<b>410,102,396</b>	<b>464,695,705</b>
<b>23.00</b>	<b>Cost of Goods Sold</b>		
	Raw materials Consumed	109,776,043	137,661,883
	Packaging materials consumed	44,257,210	47,894,455
	<b>Total materials consumption</b>	<b>154,033,252</b>	<b>185,556,338</b>
	Add: Work in process-Opening	9,821,785	10,225,565
	Less: Work in process-Closing	9,591,022	9,821,785
	<b>Total consumption</b>	<b>154,264,015</b>	<b>185,960,118</b>
	Add: Factory Overhead	126,393,661	132,322,466
	<b>Cost of production</b>	<b>280,657,676</b>	<b>318,282,584</b>
	Add: Finished goods-Opening	219,229,298	221,656,470
	<b>Production available for Sales</b>	<b>499,886,974</b>	<b>539,939,054</b>
	Less: Finished goods-Closing	220,525,748	219,229,298
	Less: Sample Expenses	1,499,214	2,320,098
	<b>Cost of Goods Sold</b>	<b>277,862,012</b>	<b>318,389,658</b>
<b>23.01</b>	<b>Raw materials consumed</b>		
	Opening Stock	189,799,690	199,826,420
	Add: Purchase during the year	113,042,243	127,635,153
	<b>Raw materials available for production</b>	<b>302,841,933</b>	<b>327,461,573</b>
	Less: Closing Stock	193,065,890	189,799,690
	<b>Total</b>	<b>109,776,043</b>	<b>137,661,883</b>
<b>23.02</b>	<b>Packaging Materials Consumed</b>		
	Opening Stock	19,283,993	20,473,058
	Add: Purchase during the year	39,931,912	46,705,390
	<b>Consumable Item available for packaging</b>	<b>59,215,905</b>	<b>67,178,448</b>
	Less: Closing Stock	14,958,695	19,283,993
	<b>Total</b>	<b>44,257,210</b>	<b>47,894,455</b>
<b>23.03</b>	<b>Factory Overhead</b>		
	Salary, Wages & Allowance	22,195,447	23,638,993
	Medical Expenses	330,250	512,705
	Food & Tiffin	93,271	109,174
	Labor Charge	1,386,147	1,622,500
	Research & Development	395,000	955,949
	Carrying Charge	2,025,783	3,457,210

Notes No.	Particulars	Amount in Taka	
		2023-2024	2022-2023
	Fuel, Oil & Lubricant	7,632,663	8,934,117
	Postage, Telephone, Mobile & Fax	199,932	234,023
	Printing and Stationary	1,346,510	2,066,750
	Repairs & Maintenance	1,025,542	1,940,655
	Electricity, Gas & Water Bills	3,396,277	2,625,134
	Store Items 23.03.01	2,463,218	2,987,844
	Other Overhead	625,450	1,722,691
	Depreciation (Annexure-A)	83,278,170	81,514,721
	<b>Total</b>	<b>126,393,661</b>	<b>132,322,466</b>
<b>23.03.01</b>	<b>Store Items</b>		
	Opening Balance	6,007,206	5,657,991
	Add: Purchase during the year	2,410,510	3,337,059
		<b>8,417,717</b>	<b>8,995,050</b>
	Less: Consumption during the year	2,463,218	2,987,844
	Closing Balance	<b>5,954,498</b>	<b>6,007,206</b>
<b>24.00</b>	<b>Operating Expenses</b>		
	Administrative Expenses 24.01	21,944,451	21,033,190
	Selling & Distribution Expenses 24.02	48,215,852	54,749,277
	<b>Total</b>	<b>70,160,303</b>	<b>75,782,467</b>
<b>24.01</b>	<b>Administrative Expenses</b>		
	Salary & Allowances	13,437,316	14,248,876
	Director Remuneration (MD)	540,000	540,000
	Postage, Telephone, Fax & Mobile bill	99,245	115,962
	Traveling & Conveyance Expenses	203,716	267,215
	Repair & Maintenance	236,383	183,225
	Electricity, Gas, Fuel & Water bill	408,520	361,851
	Printing and Stationery	334,350	386,143
	Subscriptions & Donation	40,000	45,000
	Entertainment Expenses	125,456	175,428
	Training Expense	71,315	88,607
	Audit fees including Vat	350,000	350,000
	Miscellaneous Expenses	16,866	19,742
	Photocopy, Newspaper & Periodical Expenses	50,272	57,982
	Annual fees & AGM Expenses	1,397,228	1,145,228
	Legal & Professional fees	518,900	65,000
	Fees & Renewal	623,609	341,571
	Depreciation (Annexure-A)	1,771,876	1,734,356
	Depreciation (Annexure-B-ROU)	1,719,399	907,004
	<b>Total</b>	<b>21,944,451</b>	<b>21,033,190</b>

Notes No.	Particulars	Amount in Taka	
		2023-2024	2022-2023
24.02	<b>Selling &amp; Distribution Expenses</b>		
	Salary & Allowance	28,539,692	31,767,324
	Transportation, TA & DA and Handling Expenses	3,934,995	4,293,449
	Repair and Maintenance	151,970	188,631
	Food Allowance	245,428	287,276
	Delivery Expenses	1,242,425	1,734,646
	Advertisement Expenses	47,719	152,608
	Postage, Telephone, Mobile & Fax bill	527,092	734,019
	Electricity, Water, Gas & Fuel bill	242,592	284,018
	Sales Promotion Expenses	3,502,175	3,637,878
	Travelling & Conveyance Expenses	625,432	1,095,890
	Entertainment Expenses	325,458	543,025
	Training Expense	424,674	679,087
	Samples Expenses	1,499,214	2,320,098
	Printing & Stationery	250,155	390,408
	Miscellaneous Expenses	210,214	269,343
	Depreciation (Annexure-A)	3,543,752	3,468,712
	Depreciation (Annexure-B-ROU)	2,902,866	2,902,866
	<b>Total</b>	<b>48,215,852</b>	<b>54,749,277</b>
25.00	<b>Financial Expenses</b>		
	Bank Charges	110,663	126,299
	<b>Total</b>	<b>110,663</b>	<b>126,299</b>
26.00	<b>Financial Expenses (Lease)</b>		
	Lease Expenses	926,653	195,000
	<b>Total</b>	<b>926,653</b>	<b>195,000</b>
27.00	<b>Non-operating Income</b>		
	Interest Income on Bank	37,515	15,388
	Realized Gain/(Loss) on Sale of Share (net)	(715,448)	18,557,877
	Sales of Wastage	1,006,192	2,607,530
	Dividend Income	584,178	385,772
	Sale of Sand	301,375	818,334
	<b>Total</b>	<b>1,213,812</b>	<b>22,384,901</b>
28.00	<b>Income Tax Expenses</b>		
	Current Tax	11,491,480	18,495,881
	Deferred Tax	1,979,240	1,527,052
	<b>Total</b>	<b>13,470,721</b>	<b>20,022,933</b>



Notes No.	Particulars	Amount in Taka	
		2023-2024	2022-2023
28.01	<b>Current Tax</b>		
	<b>A. Corporate Tax</b>		
	Profit before Tax		
	Less: Dividend Income	59,349,778	89,244,217
	<b>Business income including other income</b>	584,178	385,772
	Add: Depreciation as Accounting base	58,765,600	88,858,445
	Add: Interest on Lease	88,593,798	86,717,788
	Add: Depreciation as Accounting base (ROU Assets)	926,653	195,000
	<b>Sub-total:</b>	4,622,264	3,809,870
	Less: Depreciation as per Tax	152,908,316	179,581,102
	Less: Lease Payment	(97,128,279)	(93,412,550)
	<b>Taxable Profit/ Net business income</b>	(5,226,060)	(4,307,544)
	Income Tax Rate	50,553,977	81,861,008
	<b>Current Tax for business Income</b>	22.50%	22.50%
	Tax from Dividend Income @ 20%	11,374,645	18,418,727
	<b>Total current tax</b>	116,836	77,154
		<u>11,491,480</u>	<u>18,495,881</u>
	<b>Minimum tax Calculation</b>		
	<b>Calculation of Gross Receipts</b>		
	Turnover	410,102,396	464,695,705
	Non-Operating Income	1,213,812	22,384,901
	<b>Total Gross Receipts</b>	411,316,208	487,080,606
	Minimum tax rate ( 0.6% on total gross receipts)	2,467,897	2,922,484
	Tax deducted at source	6,730,339	6,993,151
	<b>Income Tax Provision whichever is higher</b>	<u>11,491,480</u>	<u>18,495,881</u>
	Income tax provision is higher between tax at corporate rate on income, Tax deducted at Source and minimum tax on gross receipts U/S 163 sub-section 5 (ka) of Income Tax Act 2023. Hence tax at corporate rate is accounted for as it is higher than the minimum tax .		
28.02	<b>Deferred Tax</b>		
	Deferred Tax Liability Closing	15.00	153,713,545
	Deferred Tax Liability Opening		151,734,305
	<b>Deferred Tax Expenses/(Income) during the year</b>		<u>1,979,240</u>
			<u>1,527,052</u>
29.00	<b>Earnings Per Share (EPS)</b>		
	a) Net Profit after Tax	45,879,058	69,221,284
	b) Total Number of Shares outstanding	103,807,000	103,807,000
	<b>Earnings Per Share (EPS) (a/b)</b>	<u>0.44</u>	<u>0.67</u>
30.00	<b>Net Asset Value (NAV) Per Share</b>		
	Total Assets	2,822,260,837	2,767,347,407
	Less: Total Liabilities	469,821,069	447,495,019
	<b>A. Net Asset Value (NAV)</b>	2,352,439,768	2,319,852,389
	B. Total Number of Share outstanding	103,807,000	103,807,000
	<b>Net Asset Value (NAV) Per Share (A/B)</b>	<u>22.66</u>	<u>22.35</u>

Notes No.	Particulars	Amount in Taka	
		2023-2024	2022-2023
31.00	Net operating cash flow per share (NOCFPS)		
	a) Net Operating Cash Flows	84,310,173	180,481,383
	b) Weighted average number of shares outstanding	103,807,000	103,807,000
	Net operating cash flow per share (NOCFPS) (a/b)	0.81	1.74

31.01 Reconciliation of Net Income or Net Profit with Cash Flows from Operating Activities (Indirect Method) the requirement of Bangladesh Securities and Exchange Commission notification no. BSEC/CMRRCD/2006-158/308/Admin/81, Dated 08 August 2018.

Particulars	Amount in (Tk.)	
	30 June 2024	30 June 2023
Net Profit before Tax	59,349,778	89,244,217
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation on Fixed Assets & ROU	93,216,063	90,527,658
Unrealized Foreign Exchange Gain/Loss		
Interst on lease	926,653	195,000
Realized Gain/(Loss) on Sale of Share		
Gain on Investment	715,448	(18,557,877)
(Increase)/Decrease in Inventories	46,119	13,697,532
(Increase)/ Decrease in Trade Receivables	(42,087,105)	11,729,137
FDR Interest Receivable		
(Increase) /Decrease in Advance, Deposits and Prepayments	(20,495,949)	10,483,549
Increase /( Decrease) in provision for expenses	(49,254)	(674,011)
Increase/(Decrease) in Liabilities for WPPF	(436,168)	(6,586,548)
Decrease/ (Decrease) in Trade Payables	(145,074)	(2,584,121)
Income tax paid	(6,730,339)	(6,993,151)
Net Cash Generated from Operating Activities	84,310,173	180,481,383

Net Cash Generated from Operation Activities (direct Method)	84,310,173	180,481,383
Difference	Nil	Nil

32.00 Information as per the Companies Act, 1994

32.01 Disclosures as per IAS 24 Related Party disclosures are as follows:

During the period the company carried out a number of transactions with related parties in the normal course of business on as arms'length basis. Name of those related parties, nature of those transaction and thire total value have been set out in accordance with the provisions of IAS-24: Related party disclosures.

Notes No.	Particulars	Amount in Taka	
		2023-2024	2022-2023

**Remuneration:**

Name of Directors	Designation	Outstanding as on June 30, 2024	Outstanding as on June 30, 2023
Dr. Md. Badrul Haque Rukan	Managing Director	45,000	45,000

As per Para-17, IAS-24:

An entity shall disclose key management personnel compensation in total and for each of the following benefits;

(a) Short-term employee benefits	540,000.00	540,000.00
(b) Post-employee benefits	Nil	Nil
(c) Other long term benefits	Nil	Nil
(d) Termination benefits and	Nil	Nil
(e) Share-based payment	Nil	Nil

As per Para-18, IAS-24

Disclosure requirements of IAS 24 Para 18 minimum disclosure shall include:

a) The amount of transaction	540,000	540,000
b) The amount of outstanding balance, including commitments	45,000	45,000
i) Their terms & condition, including whether they are secured, and the nature of the consideration to be provided in settlement.	Remuneration	Remuneration
ii) details of any guarantee	Nil	Nil
c) Provision for doubtful debts related to the amount of outstanding balance.	Nil	Nil
d) The expenses recognized during the period in respect of bad or doubtful debts due from related parties.	Nil	Nil

32.02 Disclosure as per requirement of Schedule XI, part II, Para 4 of the Companies Act, 1994 are given below:

a) Managerial Remuneration paid or payable during the financial period to the directors, including managing directors, a managing agent or manager;	540,000	540,000
b) Expenses reimbursed to the Managing Agent;	Nil	Nil
c) Commission or Remuneration payable separately to a managing agent or his associate;	Nil	Nil
d) Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.;	Nil	Nil

Notes No.	Particulars	Amount in Taka	
		2023-2024	2022-2023
	e) The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial year.;	Nil	Nil
	f) Any other perquisite or benefits in cash or in kind stating, approximate money value where practicable ;	Nil	Nil
	g) Other allowances and commission including guarantee commission; pensions etc.:	Nil	Nil
	(i) Pensions	Nil	Nil
	(ii) Gratuities	Nil	Nil
	(iii) Payments from a provident funds, in excess of own subscription and interest thereon	Nil	Nil
	(iv) Compensation for loss of office	Nil	Nil
	(v) Consideration in connection with retirement from office.	Nil	Nil

32.03 Aggregated amount of remunerating paid to all Directors and Officers during the accounting year is as follows:

Particulars	Nature of Payment	Amount in Tk	
Directors (Managing Director)	Remuneration	540,000	540,000
Officers and Executives	Salary and other Allowances	13,437,316	14,248,876
<b>Total</b>		<b>13,977,316</b>	<b>14,788,876</b>

33.00 Board Meeting attendance Fees

Board of Directors of Silco Pharmaceuticals Limited till now have not taken any board meeting attendance fees. During the year from 01.07.2023 to 30.06.2024, there were 06 (Six) Board Meeting held. The attendance status of the meeting is as follows:

Name of Board of Directors	Designation	Number of Meeting Held	Number of Meeting Attending
Mrs.Naim Fatema	Chairman	6	6
Dr. Md Badrul Haque Rukan	Managing Director	6	6
Prof. Dr. Md. Azizur Rahman	Director	6	6
Dr. Gulshan-E-Jahan	Director	6	5
Prof. Dr. Md. Harunur Rashid	Director	6	6
Dr. Mahmudul Majid Chowdhury	Director	6	6

Notes No.	Particulars	Amount in Taka	
		2023-2024	2022-2023
	Prof. Dr. Faisal Ahmed	6	6
	Director		
	Dr. Syed Burhan Uddin	6	6
	Independent Director		
	Prof. Dr. Aminur Rahman Laskar	6	6
	Independent Director		
<b>34.00</b>	<b>Received from Customers</b>		
	Sales during the year	410,102,396	464,695,705
	Add: Opening Receivables	377,507,323	389,236,460
	Less: Closing Receivables	419,594,428	377,507,323
	<b>Total</b>	<b>368,015,291</b>	<b>476,424,842</b>
<b>35.00</b>	<b>Paid to Suppliers</b>		
	Purchase during the year	155,384,665	177,677,602
	Add: Opening Trade Payables	9,749,939	12,334,060
	Less: Closing Trade Payables	9,604,865	9,749,939
	Add: Closing Advance to Supplier	79,955,311	59,996,662
	Less: Opening Advance to Supplier	59,996,662	66,509,642
	<b>Total</b>	<b>175,488,387</b>	<b>173,748,744</b>
<b>36.00</b>	<b>Paid to Employees</b>		
	Salary, Wages Including Bonus	64,712,455	70,195,192
	Add: Opening wages & Remuneration Payables	5,190,135	4,465,157
	Less: Closing wages & Remuneration Payables	5,556,965	5,190,135
	Add: Closing Advance to Employee	778,800	826,500
	Less: Opening Advance to Employee	826,500	4,586,529
	<b>Total</b>	<b>64,297,925</b>	<b>65,710,185</b>
<b>37.00</b>	<b>Paid to Others</b>		
	Factory overhead	101,734,995	105,695,629
	Administrative Expenses	7,967,135	6,244,314
	Selling Expenses	19,676,160	22,981,953
	WPPF	2,906,798	3,342,966
	Add: Opening WPPF Payables	3,342,966	9,929,514
	Less: Closing WPPF Payables	2,906,798	3,342,966
	Add: Opening Payables to electricty, gas & water, debtors & Audit fees	1,132,439	2,531,428
	Less: Closing Payables to electricty, gas & water, debtors & Audit fees	716,355	1,132,439
	Add: Closing Advance to security deposit	2,161,827	1,576,827
	Less: Opening Advance to security deposit	1,576,827	1,787,368
	Less: Sample Expenses	1,499,214	2,320,098
	Less: Depreciation (PPE)	88,593,798	86,717,788
	Less: Depreciation (ROU)	4,622,264	3,809,870
	<b>Total</b>	<b>39,007,064</b>	<b>53,192,103</b>



38.00 Disclosure as per requirement of schedule XI, Part II, Para 7 are given below:

Product Categories	Unit	Installed Capacity (Annual)	Actual Production During the year	% of Capacity utilization during the year
Tablet	Pcs.	454,500,000	253,000,000	55.67%
Capsules	Pcs.	331,280,000	167,120,000	50.45%
Liquid Syrup	Bottles	9,696,000	4,784,000	49.34%
Dry Powder of Suspension	Bottles	6,060,000	2,940,000	48.51%
SRS Saline	Pcs.	20,200,000	9,980,000	49.41%
Hand Sanitizer	Pcs.	4,242,000	2,068,000	48.75%
<b>Total</b>		<b>825,978,000</b>	<b>439,892,000</b>	<b>53.26%</b>

39.00 Disclosure as per requirement of Schedule-XI, Part-II, Note-5 of Para-3 of companies Act 1994 Employee Position (as on June 30, 2024)

Salary Range	Officer & Staff		Marketing Staff	Total Employee
	Factory	Head Office		
Below 6000	31	-	2	33
Above 6000	110	44	126	280
<b>Total</b>	<b>141</b>	<b>44</b>	<b>128</b>	<b>313</b>

40.00 General

a) **Audit Fee** : Audit fee of Tk. 3,50,000.00 represented only the audit fees and VAT thereon.

b) **Capital**

There is no capital expenditure contract has been made during the year.

c) **Contingent**

There is no claim against the company not acknowledged debt and no un-availed credit facilities, other than those in the normal course of business, available to the company on June 30, 2024.

d) Comparative figures have been re-arranged where considered necessary to ensure better comparability with the current period without causing any impact on the profit and value of assets and liabilities as reported in the financial statements.

e) **Events After The Reporting Period**: According to IAS-10, Events after the reporting period are those events, favourable and unfavorable, that occur between the end of the reporting period and the date when the financial statements are authorised for issues. The Board of directors recommended 1 % cash Dividend to all shareholders excluding directors for the financial year 2023-2024 at the board meeting held on October 31, 2024. This dividend is subject to final approval by the shareholders at the forthcoming Annual General Meeting (AGM) of the company.

f) VAT: Company's Produces both Vatable and Non-Vatable Product. The company paid VAT only on vatable items and enjoying exemption for non vatable items as per S.R.O No. 163-Law/2022/176-VAT, dated: June 01, 2022.

Note: Gross Sales of taka 458,896,084.40 including VAT, which is gross vatable sales of taka 374,084,944.40 ( including VAT) and Non-vatable sales of taka 84,811,140. The company has disclosed financial statements in net Sales of Tk. 410,102,396.

**41.00 Significant Deviation**

During the period, sales and net profit after tax decreased in comparison with corresponding same period of the previous period due to the ongoing Russia-Ukraine geopolitical situation which has caused supply chain disruptions as well as additional cost pressure for devaluation of BDT against USD as well as market uncertainties. Earnings Per Share (EPS) has decreased compared to Previous period due to decrease of net profit after tax. Net cash flows from operating activities have decrease due to decrease of customer collection as well as NOCFPS have decrease compared to previous period. NAV has increased current period compared to previous period due to increase of shareholder equity. Decrease of non-operating income of the current period compare to the previous period due to the Company Received realized loss on Sale of Share its investment.



**Silco Pharmaceuticals Limited**  
**Schedule of Property, Plant & Equipment**  
 As at June 30, 2024

Annexure-A

Particulars	Cost			Rate of Dep. (%)	Depreciation			Written Down Value as at June 30, 2024
	Balance as on 1st July 2023	Addition during the year	Balance as on June 30, 2024		Balance as on 1st July 2023	Charge during the year	Balance as on June 30, 2024	
Land and Land Development	74,854,740	-	74,854,740	-	-	-	74,854,740	
Building	1,003,745,862	79,057,696	1,082,803,558	2.50%	131,525,072	22,376,439	928,902,047	
Plant & Machinery	1,339,325,640	46,462,832	1,385,788,472	10.00%	774,707,858	57,683,062	553,397,552	
Electrical Equipment	25,519,860	355,000	25,874,860	10.00%	15,215,162	1,046,736	16,261,897	
Electrical Installation	53,863,328	-	53,863,328	10.00%	36,397,773	1,746,556	9,612,963	
Furniture & Fixture	20,424,193	1,657,900	22,082,093	10.00%	10,447,772	1,036,267	15,719,000	
Office Equipment	9,672,492	790,700	10,463,192	10.00%	5,368,446	447,620	10,598,054	
Computer	6,231,812	46,900	6,278,712	20.00%	4,109,563	431,979	4,647,126	
Transformer	12,738,550	-	12,738,550	10.00%	9,374,007	336,454	1,737,169	
Vehicles	41,300,815	-	41,300,815	10.00%	15,984,831	2,531,598	3,028,089	
Air Condition	7,713,798	2,750,000	10,463,798	20.00%	5,912,148	735,535	22,784,385	
Fire Extinguisher	6,828,180	-	6,828,180	20.00%	5,720,421	221,552	3,816,114	
<b>Balance as on June 30, 2024</b>	<b>2,602,219,270</b>	<b>131,121,028</b>	<b>2,733,340,298</b>		<b>1,014,763,054</b>	<b>88,593,798</b>	<b>1,629,983,446</b>	

Allocation of Depreciation	Rate (%)	Taka
Factory Expenses	94.00%	83,278,170
Administrative Expenses	2.00%	1,771,876
Selling & Distribution Expenses	4.00%	3,543,752
<b>Total</b>	<b>100%</b>	<b>88,593,798</b>





**Silco Pharmaceuticals Limited**  
**Schedule of Property, Plant & Equipment**  
As at June 30, 2023

Annexure-A

Particulars	Cost			Rate of Dep. (%)	Depreciation			Written Down Value as at June 30, 2023
	Balance as on 1st July 2022	Addition during the year	Balance as on June 30, 2023		Balance as on 1st July 2022	Charge during the year	Balance as on June 30, 2023	
Land and Land Development	74,854,740	-	74,854,740	-	-	-	74,854,740	
Building	880,253,923	123,491,939	1,003,745,862	2.50%	110,630,886	20,894,186	872,220,790	
Plant & Machinery	1,261,228,197	78,097,443	1,339,325,640	10.00%	717,817,600	56,890,258	564,617,782	
Electrical Equipment	25,519,860	-	25,519,860	10.00%	14,070,195	1,144,966	10,304,698	
Electrical Installation	52,608,478	1,254,850	53,863,328	10.00%	34,519,803	1,877,970	17,465,555	
Furniture & Fixture	20,106,983	317,210	20,424,193	10.00%	9,352,932	1,094,840	9,976,421	
Office Equipment	9,214,092	458,400	9,672,492	10.00%	4,913,662	454,784	4,304,046	
Computer	5,921,812	310,000	6,231,812	20.00%	3,614,885	494,679	2,122,249	
Transformer	12,738,550	-	12,738,550	10.00%	9,000,168	373,838	3,364,543	
Vehicles	41,300,815	-	41,300,815	10.00%	13,171,944	2,812,887	25,315,984	
Air Condition	7,273,298	440,500	7,713,798	20.00%	5,509,708	402,440	1,801,650	
Fire Extinguisher	6,828,180	-	6,828,180	20.00%	5,443,481	276,940	1,107,759	
<b>Balance as on June 30, 2023</b>	<b>2,397,848,928</b>	<b>204,370,342</b>	<b>2,602,219,270</b>		<b>928,045,265</b>	<b>86,717,788</b>	<b>1,587,456,216</b>	

Allocation of Depreciation	Rate (%)	Taka
Factory Expenses	94.00%	81,514,721
Administrative Expenses	2.00%	1,734,356
Selling & Distribution Expenses	4.00%	3,468,712
<b>Total</b>	<b>100%</b>	<b>86,717,788</b>



**Silco Pharmaceuticals Limited**  
**Schedule of Right of Use Asset (ROU)**

As at June 30, 2024

Particulars	Cost				Rate of Dep. (%)	Depreciation			Balance as on June 30, 2024	Written Down Value as at June 30, 2024
	Balance as on 1st July 2023	Addition during the year	Disposal	Balance as on June 30, 2024		Balance as on 1st July 2023	Charge during the year	Disposal		
Office Rent (Head Office)	969,773	3,502,479	969,773	3,502,479	33.33	969,773	1,167,493	969,773	1,167,493	2,334,986
Office Rent (DO)	1,751,240	1,655,718	1,751,240	1,655,718	33.33	1,751,240	551,906	1,751,240	551,906	1,103,812
Office Rent (BDO)	1,034,823	1,034,823	1,034,823	1,034,823	33.33	1,034,823	344,941	1,034,823	344,941	689,882
Office Rent (BOG-DO)	2,260,850	2,260,850	2,260,850	2,260,850	33.33	2,260,850	753,617	2,260,850	753,617	1,507,234
Office Rent (KBO-DO)	1,241,788	1,241,788	1,241,788	1,241,788	33.33	1,241,788	413,929	1,241,788	413,929	827,859
Office Rent (MBO-DO)	1,241,788	1,241,788	1,241,788	1,241,788	33.33	1,241,788	413,929	1,241,788	413,929	827,859
Office Rent (NDO-DO)	1,783,080	1,783,080	1,783,080	1,783,080	33.33	1,783,080	594,360	1,783,080	594,360	1,188,720
Office Rent (CDO-DO)	1,146,266	1,146,266	1,146,266	1,146,266	33.33	1,146,266	382,089	1,146,266	382,089	764,177
<b>Balance as on June 30, 2024</b>	<b>11,429,609</b>	<b>13,866,793</b>	<b>11,429,609</b>	<b>13,866,793</b>		<b>11,429,609</b>	<b>4,622,264</b>	<b>11,429,609</b>	<b>4,622,264</b>	<b>9,244,529</b>



**Silco Pharmaceuticals Limited**  
**Schedule of Right of Use Asset (ROU)**  
As at June 30, 2023

Particulars	Cost			Rate of Dep. (%)	Depreciation			Balance as on June 30, 2023	Written Down Value as at June 30, 2023
	Balance as on 1st July 2022	Addition during the year	Disposal		Balance as on 1st July 2022	Charge during the year	Disposal		
Office Rent (Head Office)	969,773	-	-	33.33	646,516	323,258	-	969,773	-
Office Rent (DO)	1,751,240	-	-	33.33	1,167,494	583,747	-	1,751,240	-
Office Rent (BDO)	1,034,823	-	-	33.33	689,882	344,941	-	1,034,823	-
Office Rent (BOG-DO)	2,260,850	-	-	33.33	1,507,234	753,617	-	2,260,850	-
Office Rent (KBO-DO)	1,241,788	-	-	33.33	827,858	413,929	-	1,241,788	-
Office Rent (MBO-DO)	1,241,788	-	-	33.33	827,858	413,929	-	1,241,788	-
Office Rent (NDO-DO)	1,783,080	-	-	33.33	1,188,720	594,360	-	1,783,080	-
Office Rent (CDO-DO)	1,146,266	-	-	33.33	764,178	382,089	-	1,146,266	-
<b>Balance as on June 30, 2023</b>	<b>11,429,609</b>	<b>-</b>	<b>-</b>		<b>7,619,740</b>	<b>3,809,870</b>	<b>-</b>	<b>11,429,609</b>	<b>-</b>

